Overview of the new oral anticoagulants: opportunities and challenges.
about
Management of Venous Thromboembolism: Recent Advances in Oral Anticoagulation TherapyTherapeutic and clinical aspects of portal vein thrombosis in patients with cirrhosisNew Insights into the Pros and Cons of the Clinical Use of Vitamin K Antagonists (VKAs) Versus Direct Oral Anticoagulants (DOACs)Rivaroxaban as an Antithrombotic Agent in a Patient With ST-Segment Elevation Myocardial Infarction and Left Ventricular Thrombus: A Case Report.Selection and characterization of a DNA aptamer inhibiting coagulation factor XIa.Myeloid-related protein-14 regulates deep vein thrombosisEffects of Five Bangladeshi Plant Extracts on In vitro Thrombolysis and Cytotoxicity.Factor XI as a Therapeutic Target.Effectiveness of Inferior Vena Cava Filters without Anticoagulation Therapy for Prophylaxis of Recurrent Pulmonary Embolism.The reversal effect of prothrombin complex concentrate (PCC), activated PCC and recombinant activated factor VII against anticoagulation of Xa inhibitor.Real-life experience with the specific reversal agent idarucizumab for the management of emergency situations in dabigatran-treated patients: a series of 11 cases.Evaluating coagulation tests in patients with atrial fibrillation using direct oral anticoagulants.New oral anticoagulant prescription rate and risk of bleeding in an Italian region.Rendering factor Xa zymogen-like as a therapeutic strategy to treat bleeding.Real-Life Management of Venous Thromboembolism With Rivaroxaban: Results From EXperience VTE, an Italian Epidemiological Survey.Safety and Interactions of Direct Oral Anticoagulants with Antiarrhythmic Drugs.Designing and Implementing an Electronic Patient Registry to Improve Warfarin Monitoring in the Ambulatory Setting.Genetic testing to guide warfarin dosing: Impact of direct oral anticoagulants.Venous Thromboembolic Disease in Children and Adolescents.The Intrinsic Pathway of Coagulation as a Target for Antithrombotic Therapy.Activated Factor X Induces Endothelial Cell Senescence Through IGFBP-5Local Production of Activated Factor X in Atherosclerotic Plaque Induced Vascular Smooth Muscle Cell Senescence.In vitro, antithrombotic and bleeding time studies of BMS-654457, a small-molecule, reversible and direct inhibitor of factor XIa.Rivaroxaban-Induced Hypersensitivity Syndrome.Bleeding risk in patients using oral anticoagulants submitted to surgical procedures in dentistry: a systematic review protocol.Prescribing of NOACs has outnumbered warfarin: exploring how physicians choose anticoagulant treatments.Accuracy and consistency of anti-Xa activity measurement for determination of rivaroxaban plasma levels.Structural Basis for Activity and Specificity of an Anticoagulant Anti-FXIa Monoclonal Antibody and a Reversal Agent.Generation and characterization of aptamers targeting factor XIa.A rapid pro-hemostatic approach to overcome direct oral anticoagulants.Heart Failure as a Risk Factor for Stroke.
P2860
Q26766303-F264A965-F471-41A3-9029-A5FB488E24D4Q26774531-C2F8BC09-6F24-49AB-A1AF-A80B4B8327F1Q28081366-831616C3-3A46-4576-99E2-87D5F221BF5CQ33693257-96EFE6BE-4EAC-439A-AA79-D841D829BE40Q33704680-B1447732-3F1C-4643-85DD-10D0571AE91EQ33752316-A9DCC3D7-E299-424A-A946-66AE3C4F0D6DQ37006922-DD23CEE3-66A6-4202-86B0-A0253373F486Q37033749-81374AC1-78F0-413A-A957-133761EEDE5EQ37211369-7ECBA9A3-99C1-4C40-B1EC-62B56A28B4C9Q37655400-AEB13512-D8F3-4391-9FB6-CA7B0D896801Q37680793-22C957F7-5534-4B95-8364-2F9BF0DCC40DQ38608242-00F5A3A3-A6F6-4F9A-AC1C-87BFFFFB0FAFQ38652425-40C42E0B-7A21-4708-B74D-141F39A6FC08Q38660256-16095CEA-C98A-4229-805F-1FDA1E0ACA5FQ38674332-8A2B8E5C-F0D7-48C9-BDE2-B2D65CCC4E07Q38687974-CDF838B6-EF33-4428-8CED-45E8C3A916E2Q38710143-6D8E9620-5FF4-4B99-9EA0-A11A3FD193F4Q38867357-30E7E0E0-4A92-4ACA-9252-60E4CF86CCEDQ38954315-6734B0ED-D6B9-4D4B-B83A-14C6C73D2DE3Q38956551-52635506-B585-48C6-8E65-AA07914058D5Q41484530-09CE8802-5804-4578-BD2F-ACF67A346D68Q45875545-7E96CAEC-3E54-4900-9CE0-D4C64DCFD119Q46688667-2B72A2D2-4424-4FEA-99AC-FAB7A2833E4FQ47119592-A063C8A9-ED74-4DC7-8BA8-5FF68130C443Q47280600-7A4D3847-C03D-4246-A9E4-90C3BAAF5961Q47834184-CE8FEB73-5BDB-4066-9742-2CF1C6B3ABD1Q48336080-C2D927E3-053D-49FE-84D3-DB359331531CQ50034387-FE6D0A3A-9E5F-4F8C-BE5A-34755025C3C1Q50566748-9F4BE332-6949-4EF3-B2CD-41F8E5C25187Q51618025-D4103C92-466B-48D1-B539-0CE5412A6CE6Q55008079-7E7AF48B-866C-448C-96F3-3B1F4A3DABAA
P2860
Overview of the new oral anticoagulants: opportunities and challenges.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Overview of the new oral anticoagulants: opportunities and challenges.
@en
type
label
Overview of the new oral anticoagulants: opportunities and challenges.
@en
prefLabel
Overview of the new oral anticoagulants: opportunities and challenges.
@en
P2093
P1476
Overview of the new oral anticoagulants: opportunities and challenges.
@en
P2093
Calvin H Yeh
Jeffrey I Weitz
Kerstin Hogg
P304
P356
10.1161/ATVBAHA.115.303397
P407
P577
2015-03-19T00:00:00Z